Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection

PURPOSE: There are no reliable biomarkers to guide treatment for patients with borderline resectable pancreatic cancer (BRPC) in the neoadjuvant setting. We used plasma circulating tumor DNA (ctDNA) sequencing to search biomarkers for patients with BRPC receiving neoadjuvant mFOLFIRINOX in our phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Dong-Hoon, Yoon, Hyunseok, Kim, Kyu-pyo, Ryoo, Baek-Yeol, Lee, Sang Soo, Park, Do Hyun, Song, Tae Jun, Hwang, Dae Wook, Lee, Jae Hoon, Song, Ki Byung, Kim, Song Cheol, Hong, Seung-Mo, Hyung, Jaewon, Yoo, Changhoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582539/
https://www.ncbi.nlm.nih.gov/pubmed/37139665
http://dx.doi.org/10.4143/crt.2023.452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582539/
https://www.ncbi.nlm.nih.gov/pubmed/37139665
http://dx.doi.org/10.4143/crt.2023.452

Ejemplares similares